• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    PD-L1 expression and its effect on clinical outcomes of EGFR-mutant NSCLC patients treated with EGFR-TKIs

    2018-12-07 06:21:40YuchenBaiXiaoxiaChenLikunHouJunQianTaoJiangCaicunZhouMaciejCiebiadaDepartmentofGeneralandOncologicalPulmonologyUniversityClinicalHospitalNorbertBarlickiMedicalUniversityofLodzLodzPolandDepartmentofUrologyShanghaiGeneralH
    Cancer Biology & Medicine 2018年4期

    Yuchen Bai, Xiaoxia Chen, Likun Hou, Jun Qian, Tao Jiang, Caicun Zhou, Maciej CiebiadaDepartment of General and Oncological Pulmonology, University Clinical Hospital Norbert Barlicki, Medical University of Lodz, Lodz 0, Poland; Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 000, China; Department of Medical Oncology; Department of Pathology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai 00, China; Department of Medical Oncology, Suzhou Cancer Center, the Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou 1000, China

    ABSTRACT Objective: Epidermal growth factor receptor (EGFR) activation was reported to upregulate programmed death-ligand 1 (PD-L1)expression in lung cancer cells and subsequently contribute to immune escape, indicating its critical role in EGFR-driven lung tumors. This study characterized PD-L1 expression in patients with surgically resected EGFR-mutant non-small cell lung cancer(NSCLC). The effect of PD-L1 expression on clinical outcomes was also investigated in advanced EGFR-mutant NSCLC treated with EGFR-tyrosine kinase inhibitors (TKIs).Methods: In total, 73 patients with surgically resected NSCLC and EGFR mutations were identified. PD-L1 expression and CD8+tumor-infiltrating lymphocyte (TIL) density were assessed by immunohistochemistry. A literature review of publications that assessed the predictive and prognostic value of PD-L1 expression in advanced EGFR-mutant NSCLC patients treated with EGFRTKIs was performed.Results: Nineteen (26.0%) patients were positive for PD-L1 expression, which was significantly associated with concomitant KRAS mutation (P = 0.020) and marginally associated with higher CD8+ TILs density (P = 0.056). Positive PD-L1 expression was associated with markedly inferior overall survival (OS) in multivariate analysis (P = 0.032). The combination of PD-L1 and CD8+TILs expression could be used to stratify the population into three groups with distinct prognoses. A meta-analysis of six publications showed that positive PD-L1 expression was not associated with OS [hazard ratio (HR) = 0.90; 95% confidence interval (CI), 0.42–1.38] or progression-free survival (HR = 1.03; 95 CI, 0.73–1.33) in advanced EGFR-mutant NSCLC patients receiving EGFR-TKIs.Conclusions: PD-L1 expression tended to correlate with CD8+ TIL expression, concomitant KRAS mutation, and poor survival in surgically resected EGFR-mutant NSCLC. PD-L1 expression was neither the predictive nor the prognostic factor in advanced EGFR-mutant NSCLC patients treated with EGFR-TKIs.

    KEYWORDS Non-small cell lung cancer; EGFR mutation; PD-L1; CD8; survival

    Introduction

    Targeted therapy on epidermal growth factor receptor(EGFR)-activating mutations has revolutionized the treatment landscape of patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC)1. Several large-scale phase 3 trials have demonstrated the superior efficacy of firstand second-generation EGFR tyrosine kinase inhibitors(TKIs) to standard platinum-based chemotherapy in the first-line setting2-4. However, almost all responders acquired drug resistance after 9–12 months (acquired resistance), and 30% of the initial cohorts showed no response to EGFR-TKIs(primary resistance)1,5-7. A series of resistance mechanisms have been associated with primary and/or acquired resistance, including Bcl-2 family member (BIM) deletion polymorphism, second site mutations, downstream or bypass signaling pathway activation, and histological transformation; however, 25%–30% of acquired resistance and half of primary resistance mechanisms remain undetermined1,7. Therefore, drug resistance is the major challenge for the application of EGFR-TKI in EGFR-mutant NSCLC. There is an urgent need to identify more effective biomarkers to better predict the efficacy of EGFR-TKIs.

    Immune checkpoints are orchestrated by a set of costimulatory and co-inhibitory molecules to regulate the activation and effector functions of tumor-infiltrating lymphocytes (TILs)8. Blockade of inhibitory immune checkpoints by antibodies may release the immune inhibition of effector T cells, especially CD8+ T cells9. To date,therapeutic antibodies targeting programmed cell death 1 (PD-1) and its ligand (PD-L1) have been associated with remarkable response rates in various cancers and are another significant breakthrough in the treatment of patients with advanced NSCLC. Three PD-1/PD-L1 antibodies, including nivolumab, pembrolizumab, and atezolizumab, have been approved for second-line or subsequent treatment of advanced NSCLC for their promising anti-tumor effect compared to that of standard chemotherapy10-13.Furthermore, pembrolizumab was approved in the first-line setting for patients with PD-L1 expression ≥ 50%14,15.However, in clinical practice, Gainor et al.16reported a limited effect of PD-1/PD-L1 inhibitors in patients with EGFR-mutant NSCLC. A recent phase 2 clinical study reported a 12.2% objective response rate (ORR) to an anti-PD-L1 antibody among EGFR-mutant NSCLC patients, with at least 25% of tumor cells expressing PD-L1, compared to an ORR of 3.6% in those with PD-L1 expression < 25%17,suggesting the clinical value of PD-L1 expression in EGFR-mutant NSCLC patients treated with anti-PD-L1 antibody.However, there are limited data to characterize the PD-L1 expression in EGFR-mutant NSCLC patients. A recent preclinical study demonstrated that the expression of mutant EGFR in bronchial epithelial cells could significantly induce PD-L1 expression and that EGFR-TKIs could reduce PD-L1 expression in NSCLC cell lines with activated EGFR18,indicating a potential relationship between PD-L1 expression and EGFR mutations in NSCLC. Several groups, therefore,investigated the predictive and prognostic value of PD-L1 expression on EGFR-mutant NSCLC patients treated with EGFR-TKIs. However, their findings were paradoxical. Lin et al.19reported that PD-L1 expression was associated with a better response to EGFR-TKI and longer survival, while Tang et al.20suggested that PD-L1 expression was neither the predictive nor the prognostic factor in EGFR-mutant NSCLC patients treated with EGFR-TKIs.

    Therefore, the current study aimed to characterize PD-L1 expression in patients with surgically resected EGFR-mutant NSCLC and to investigate the effect of PD-L1 expression on clinical outcomes in patients with advanced EGFR-mutant NSCLC treated with EGFR-TKIs. Because the antitumor effect of anti- PD-1/PD-L1 antibodies is mainly dependent on the proliferation and activation of CD8+ TILs8,9, we further evaluated the prognostic value of the combination of PD-L1 expression and CD8+ TIL density in surgically resected NSCLC with EGFR mutations.

    Patients and methods

    Patient cohort

    We retrospectively identified patients who underwent surgical resection of the lung (lobectomy or pulmonectomy)due to the histologically-confirmed NSCLC, between 2011 and 2015, at Shanghai Pulmonary Hospital and our cooperative medical centers. The major patient baseline characteristics including age, sex, smoking history, histology[World Health Organization (WHO) classification]21, and stage of NSCLC at initial diagnosis were collected. Never smoker was defined as a person who has smoked fewer than 100 cigarettes during their lifetime. This study was conducted in accordance with the provisions of the Declaration of Helsinki and was approved by the ethics committee of Shanghai Pulmonary Hospital. The exclusion criteria included histologically-confirmed SCLC, stage IIIB-IV before surgery, and chemotherapy and/or radiotherapy administered before surgery. Patients who could not provide adequate samples for EGFR detection and PD-L1/CD8 staining or who disagreed with the study protocols were ineligible.

    PD-L1 expression analysis

    PD-L1 expression was evaluated by immunohistochemistry(IHC) as described previously22. In brief, tumor sections of formalin-fixed and paraffin-embedded specimens were treated with 3% H2O2for 10 min, blocked with 5% goat serum, and incubated with a primary anti-human PD-L1 antibody (#13684, clone E1L3N, Cell Signaling Technology,Danvers, MA, diluted 1:200). Next, a peroxidase-labeled secondary antibody (REAL EnVision Detection Reagent Peroxidase Rabbit/Mouse, DAKO, Denmark) was applied to the sections for 30 min at room temperature. PD-L1 positive/negative expression was defined using a cut-off value of 5%23-26.

    CD8+ TIL analysis

    A mouse anti-CD8 monoclonal antibody (M7103, clone C8144B, DAKO, Denmark) was utilized for CD8+ TIL density assessment as described previously27,28. TILs were enumerated on immunostained CD8 preparations and scored using a four-tier scale (details in supplemental file).The cut-off point for high/low CD8+ TIL expression was 5%.

    EGFR and KRAS mutation detection

    EGFR and KRAS mutation analyses were conducted at Shanghai Pulmonary Hospital & Thoracic Cancer Institute,Tongji University School of Medicine (Shanghai, China). The samples were tested using an Amplification Refractory Mutation System (ARMS) as previously described (Amoy Diagnostics Co., Ltd., Xiamen, China)22,29,30.

    Meta-analysis

    We performed a publication search of the PubMed/Medline, EMBASE, Google Scholar, Cochrane Library, and Web of Science databases through December 31, 2017, using“l(fā)ung cancer” and “PD-L1” and “EGFR-TKI” and their related words. Data on the relationship between PD-L1 expression and overall survival (OS), progression-free survival (PFS), and clinicopathological characteristics in EGFR-mutant NSCLC patients treated with EGFR-TKIs were collected from publications meeting the eligibility criteria(Supplementary Table S1). The details of our methodology are described in the supplemental file.

    Statistical analysis

    Categorical variables were analyzed using the Chi-square or Fisher’s exact tests. Continuous variables were analyzed by analysis of variance and Tukey’s multiple comparison tests.Kaplan-Meier curves were used to assess patient survival, and log-rank tests were used to evaluate the significance of differences between two or four groups. Cox proportional hazards models were used for uni- and multivariate survival analyses to calculate the hazard ratios (HRs) and corresponding 95% confidence intervals (CIs). The OS was calculated from the date of lung cancer diagnosis to death from any cause or was censored at the last follow-up date.P-values less than 0.05 (two-sided) were considered to be significant. Meta-analysis was conducted using STATA version 12.0 (Stata Corporation, TX). All statistical analyses were performed using IBM SPSS Statistics for Windows,version 22.0 (IBM Corp., Armonk, NY, USA).

    Results

    Characterization of PD-L1 expression in EGFR-mutant NSCLC

    In total, 201 patients with surgically resected NSCLC were initially enrolled. After EGFR detection, 73 patients with surgically resected EGFR-mutant NSCLC were finally identified. Most (63.0%) were < 65 years old at the time of diagnosis. Forty-two (57.5%) of the patients were female and 44 (60.3%) were never-smokers. The most predominant histological type was adenocarcinoma (71 patients). Three patients (4.1%) had concomitant KRAS mutations. Nineteen patients (26.0%) had positive PD-L1 expression and 22 (30.1%) had high CD8+ TILs density. Representative images of IHC for PD-L1 expression and CD8+ TILs are shown in Supplementary Figure S1. The clinical features of the 73 patients are summarized in Table 1.

    There was a significant correlation between PD-L1 expression and concomitant KRAS mutations (P = 0.020).Patients with high CD8+ TIL density were more likely to have positive PD-L1 expression, but the relationship did not reach statistical significance (P = 0.056). There were no significant differences in PD-L1 expression in terms of age(P = 0.570), gender (P = 0.297), smoking status (P = 0.429),pathologic types (adenocarcinoma vs. non-adenocarcinoma)(P = 0.973), pathologic stages (I/IIIA vs. IIIB/IV) (P = 0.591),and lymph node metastasis (P = 0.661).

    Prognostic value of PD-L1 expression in surgically resected NSCLC with EGFR mutation

    The median follow-up time was 25.7 months (range, 5.6–54.9 months). Univariate analysis revealed that patients with positive PD-L1 expression showed a marginally shorter OS than that in patients with negative expression (HR = 2.339,95% CI: 0.992–9.835; P = 0.057) (Table 2 and Figure 1A).High CD8+ TIL density tended to be associated with longer OS but it did not reach the statistical significance (HR =0.409, 95% CI: 0.185–1.246; P = 0.138) (Table 2 and Figure 1B). Other factors including gender, age, smoking status,lymph node metastasis, and EGFR mutant types were not associated with OS (Table 2). Multivariate analyses suggested that positive PD-L1 expression was significantly associated with a shorter OS (HR = 2.995, 95% CI: 1.097–8.178; P =0.032) (Table 2). While patients with high CD8+ TIL expression showed a longer OS than that in those with low CD8+ TIL expression, the difference was not statisticallysignificant (HR = 0.296, 95% CI: 0.080–1.103; P = 0.070)(Table 2).

    Table 1 Baseline characteristics of the study population

    We further assigned the population into four groups according to PD-L1 and CD8+ TIL expression. The median OS was not reached in the PD-L1+/CD8-high and PD-L1-/CD8-high expression groups but was 29.0 months in the PD-L1+/CD8-low group and 45.0 months in the PD-L1-/CD8-low group (P = 0.056, Figure 1C). Patients with PD-L1-/high CD8+ TIL density expression had the longest OS (HR =0.196, P = 0.072), while the PD-L1+/CD8-low group had the shortest OS (HR = 3.087, P = 0.020) (Supplementary Figure S2).

    Features of the studies included in the metaanalysis

    A total of 192 potentially relevant studies were screened.Most of the excluded publications were reviews, comments,duplications, or studies with incomplete data. The current study assessed 648 cases from six publications19,20,31-34to investigate both the predictive and prognostic value of PD-L1 expression in advanced EGFR-mutant NSCLC patients treated with EGFR-TKIs. The main features of the eligible studies are shown in Table 3 and Supplementary Table S2.In addition, prognostic and predictive data on OS and PFS were obtained from the included studies. Figure 2 depicts a flowchart of publication inclusion.

    Predictive and prognostic value of high PD-L1 expression in EGFR-mutant NSCLC treated with EGFR-TKIs

    A meta-analysis was performed to evaluate the overall effect of positive PD-L1 expression in the studies containing predictive and prognostic data. The pooled results showed that positive PD-L1 expression was not correlated with OS(HR = 0.90, 95% CI: 0.42–1.38; P > 0.05; Figure 3A).Similarly, the pooled results indicated that positive PD-L1 expression was not associated with PFS (HR = 1.03, 95% CI:0.73–1.33; P > 0.05; Figure 3B). Both results showed high heterogeneity (I2= 80.3%, P < 0.001; I2= 60.8%; P = 0.013;respectively).

    Publication bias

    Sensitivity analysis was conducted by deleting one study at one time to assess its effect on the pooled HRs. Deletion of the study by Meniawy et al.31slightly decreased the heterogeneity in the analysis of pooled HRs of PFS and OS.No other studies influenced the pooled results. Begg’s funnel plots and Egger’s tests were used to evaluate the publication bias. The Begg’s funnel plot was symmetric, and Egger’s tests suggested no evidence of publication bias (Supplementary Figure S3).

    Discussion

    Emerging evidence suggested that blocking PD-1/PD-L1 showed a limited efficacy in patients with EGFR-mutant NSCLC. A preclinical study reported that EGFR activation could regulate PD-L1 expression in lung cancer, indicating a sophisticated interaction between EGFR mutations andPD-L1 expression. Improved understanding of PD-L1 expression in EGFR-mutant NSCLC would contribute to the development of more effective immunotherapy. Additionally,clarifying the predictive and prognostic value of PD-L1 expression in EGFR-mutant NSCLC patients treated with EGFR-TKIs would be helpful to precisely determine the populations who could most benefit from EGFR-TKIs therapy. To achieve these goals, the current study systematically investigated the clinicopathological features of PD-L1 expression in surgically resected EGFR-mutant NSCLC and the effect of this expression on clinical outcome patients with advanced EGFR-mutant NSCLC treated with EGFR-TKIs. Our results showed that positive PD-L1 expression was significantly correlated with concomitant KRAS mutations and seemed to be associated with high CD8+ TILs density without statistical significance, mainly due to the small sample size. Positive PD-L1 expression was associated with a significantly shorter OS, and the combination of PD-L1 and CD8+ expression could further stratify the population into three groups with distinct prognoses. Furthermore, a meta-analysis of six publications indicated that positive PD-L1 expression was neither a predictive nor a prognostic factor in advanced EGFR-mutant NSCLC patients treated with EGFR-TKIs.

    Table 2 Univariate and multivariate analyses of clinical parameters on OS in patients with EGFR muttaions.

    Figure 1 Prognostic value of PD-L1 expression (A) CD8 TILs expression (B) and combination of PD-L1 and CD8 TILS expression (C) in surgically resected NSCLC with EGFR mutation.

    Several studies have reported a positive association between EGFR mutations and positive PD-L1 expression in completely resected NSCLC20,35-37. However, few studies have characterized PD-L1 expression in patients with EGFR-mutant NSCLC. In our study, we observed that positive PD-L1 expression was significantly correlated with concomitant KRAS mutations in patients with EGFR-mutant NSCLC. PD-L1 is frequently highly expressed in NSCLC with driver mutations, which subsequently activates key oncogenic pathways such as PI3K-AKT and RAS-MAPK. Hence, it is anticipated that more cases with high PD-L1 expression had concomitant EGFR and KRAS mutations. Notably, only three patients in the present study had concomitant EGFR and KRAS mutations. We should interpret this result with caution. In addition, positive PD-L1 expression was marginally significantly associated with high CD8+ TIL density in this population, suggesting high PD-L1 expression of CD8+ TILs in EGFR-mutant NSCLC. Further investigation of the potential role of PD-1/PD-L1 pathway in inhibiting CD8+ TIL function in EGFR-mutant NSCLC is required.

    Figure 2 The flowchart of publication selection.

    We further evaluated the prognostic value of PD-L1 expression in surgically resected NSCLC with EGFR mutations. As expected, positive PD-L1 expression was significantly associated with inferior OS and CD8+ TIL density was marginally correlated with a longer OS. When we combined PD-L1 expression and CD8+ TIL density, the total populations could be divided into three groups with distinct prognoses. Similarly, a large number of studies consistently reported positive PD-L1 expression to be an independent negative prognostic factor in NSCLC. In 2014, Azuma et al.35assessed the prognostic value of PD-L1 expression in 164 surgically resected NSCLC, reporting high PD-L1 expression to be significantly associated with a shorter OS independently of other factors. Two recent meta-analyses also demonstrated the prognostic value of PD-L1 expression in NSCLC.However, another meta-analysis reported no statistically significant difference between PD-L1 expression and prognosis in patients with NSCLC38,39. Of note, the driver gene mutations of the populations in these studies were unknown. Thus, high-quality studies with larger sample sizes are needed to determine the prognostic value of PD-L1 expression in NSCLC with specific driver mutations. Our finding of the prognostic value of PD-L1 expression combined with CD8+ TIL density was consistent with those of other studies28. For example, Tokito et al.28observed that a combination of a lack of PD-L1 expression and CD8+ TIL density was significantly associated with favorable survival in patients with locally advanced NSCLC receiving concurrent chemoradiotherapy, indicating that PD-L1 expression in combination with CD8+ TIL density was a useful predictive biomarker in patients with stage III NSCLC. These results suggested that the combination of PD-L1 expression and CD8+ TIL density may be useful to predict the prognosis and efficacy of immunotherapy in NSCLC.

    To clarify the predictive and prognostic value of PD-L1 expression in EGFR-mutant NSCLC patients treated with EGFR-TKIs, we conducted a meta-analysis of six eligible publications. Although preclinical studies reported that EGFR activation could induce PD-L1 expression to facilitate immune escape and that EGFR-TKI could significantly down-regulate PD-L1 expression in EGFR-mutant NSCLC cells18,35, the pooled results indicated that positive PD-L1 expression was not correlated with OS or PFS in this population. Whether PD-L1 expression is a reliable biomarker for EGFR-TKI treatment in advanced EGFR-mutant NSCLC patients requires further investigation.

    The current study had several limitations. First, the number of publications included in the meta-analysis was relatively small and all were retrospective studies. Second,publication bias is inevitable in this area of research. We identified several abstracts published at meetings withoutfurther detailed publications and excluded these abstracts from the meta-analysis. Third, the quality of data was heterogeneous due to a multitude of confounding factors(laboratory conditions, PD-L1 antibody, cutoff values of PD-L1 expression, etc.) that made direct comparisons difficult.

    Table 3 Baseline characteristics of included studies

    Figure 3 Meta-analysis to evaluate the predictive (A) and prognostic (B) value of high PD-L1 expression in EGFR-mutant NSCLC treated with EGFR-TKIs.

    In conclusion, the present study showed that PD-L1 expression had a particular clinicopathological feature and was correlated with a shorter OS in patients with EGFR-mutant NSCLC. The combination of PD-L1 expression and CD8+ TIL density more precisely differentiated subpopulations with distinct prognoses after surgery. Positive PD-L1 expression was neither the predictive nor the prognostic factor in EGFR-mutant NSCLC patients treated with EGFR-TKIs. These results suggested that a meaningful graded prognostic assessment for patients with surgical EGFR-mutant NSCLC should incorporate PD-L1 and CD8+TILs and that PD-L1 expression should not be evaluated as a biomarker of EGFR-TKIs.

    Acknowledgements

    This study was supported in part by grants from the National Natural Science Foundation of China (Grant No. 81672286,81772467 and 81874036), “Shuguang Program” supported by Shanghai Education Development Foundation and Shanghai Municipal Education Commission (Grant No. 16SG18), the Chronic Diseases Program of Shanghai Shen Kang Pharmaceutical Development Co. Ltd (Grant No. SHDC 12015314).

    Conflict of interest statement

    No potential conflicts of interest are disclosed.

    午夜激情欧美在线| 国产成人影院久久av| 人妻少妇偷人精品九色| 十八禁国产超污无遮挡网站| 一个人看的www免费观看视频| 成人三级黄色视频| 一夜夜www| 秋霞在线观看毛片| 欧美日韩国产亚洲二区| 久久热精品热| 亚洲欧洲日产国产| 99riav亚洲国产免费| 如何舔出高潮| 97超碰精品成人国产| 亚洲电影在线观看av| 久久精品国产亚洲av香蕉五月| 国产高清有码在线观看视频| 免费看日本二区| 免费观看精品视频网站| 国产精品久久久久久久电影| 中文欧美无线码| 国产一区二区在线观看日韩| 男女下面进入的视频免费午夜| 在线观看一区二区三区| 日韩制服骚丝袜av| 有码 亚洲区| 日本av手机在线免费观看| 男女视频在线观看网站免费| 春色校园在线视频观看| 简卡轻食公司| 国产精品久久久久久久久免| 亚洲国产精品国产精品| 欧美最黄视频在线播放免费| 91精品一卡2卡3卡4卡| www.av在线官网国产| 国产三级在线视频| 亚洲av第一区精品v没综合| 成人鲁丝片一二三区免费| 欧美日韩国产亚洲二区| eeuss影院久久| а√天堂www在线а√下载| 啦啦啦啦在线视频资源| 大香蕉久久网| 国产精品久久久久久精品电影| 日韩av在线大香蕉| 晚上一个人看的免费电影| 亚洲国产日韩欧美精品在线观看| 男人舔奶头视频| a级毛片免费高清观看在线播放| 成人性生交大片免费视频hd| 国产亚洲精品av在线| 亚洲精品日韩在线中文字幕 | 国产在线精品亚洲第一网站| 国产精品一区二区性色av| 精品午夜福利在线看| 男插女下体视频免费在线播放| 国产综合懂色| 日本黄色视频三级网站网址| 国产成年人精品一区二区| 男人的好看免费观看在线视频| 在线播放国产精品三级| 国产女主播在线喷水免费视频网站 | 国产午夜精品一二区理论片| 久久久久久九九精品二区国产| 日韩精品有码人妻一区| 一本久久中文字幕| 亚洲在线观看片| 亚洲国产高清在线一区二区三| 久久中文看片网| 嫩草影院精品99| 久久精品久久久久久久性| 欧美人与善性xxx| 亚洲国产精品sss在线观看| 中国国产av一级| 成人鲁丝片一二三区免费| 特级一级黄色大片| 男人舔女人下体高潮全视频| 18禁裸乳无遮挡免费网站照片| 高清在线视频一区二区三区 | 1000部很黄的大片| 偷拍熟女少妇极品色| 国产精品伦人一区二区| 熟女电影av网| 国产私拍福利视频在线观看| 久久午夜亚洲精品久久| 成人永久免费在线观看视频| 美女大奶头视频| 一区二区三区四区激情视频 | 一边亲一边摸免费视频| 非洲黑人性xxxx精品又粗又长| 尾随美女入室| 菩萨蛮人人尽说江南好唐韦庄 | 51国产日韩欧美| 在线国产一区二区在线| 亚洲精品成人久久久久久| av视频在线观看入口| 蜜桃久久精品国产亚洲av| 国产精品一区二区在线观看99 | 精品不卡国产一区二区三区| 哪里可以看免费的av片| 青春草国产在线视频 | 亚州av有码| 久久久国产成人免费| 亚洲人成网站在线观看播放| 深夜a级毛片| 日日干狠狠操夜夜爽| 亚洲美女搞黄在线观看| av.在线天堂| 久久中文看片网| 日韩亚洲欧美综合| 伦精品一区二区三区| 26uuu在线亚洲综合色| 久久午夜福利片| 国产在线精品亚洲第一网站| 欧美日本亚洲视频在线播放| 亚洲五月天丁香| 日本一本二区三区精品| 成人毛片60女人毛片免费| 九九热线精品视视频播放| 日韩一区二区三区影片| 亚洲色图av天堂| 亚洲综合色惰| 久久人人爽人人片av| 日韩国内少妇激情av| 成人三级黄色视频| 欧美成人一区二区免费高清观看| 免费人成在线观看视频色| 亚洲av中文av极速乱| 天美传媒精品一区二区| 在线播放国产精品三级| 天天躁夜夜躁狠狠久久av| 偷拍熟女少妇极品色| 99热这里只有精品一区| 日本免费一区二区三区高清不卡| 欧美激情在线99| 最近最新中文字幕大全电影3| 亚洲中文字幕一区二区三区有码在线看| 天堂√8在线中文| 99热这里只有是精品在线观看| 免费人成视频x8x8入口观看| 国产精品永久免费网站| 亚洲av中文av极速乱| 91在线精品国自产拍蜜月| 色尼玛亚洲综合影院| 国产极品精品免费视频能看的| 麻豆国产97在线/欧美| 免费观看的影片在线观看| 99久国产av精品| 欧美日本视频| 美女脱内裤让男人舔精品视频 | 欧美一区二区亚洲| 日韩亚洲欧美综合| 亚洲国产精品久久男人天堂| 搞女人的毛片| 午夜福利在线在线| 久久精品影院6| 亚洲婷婷狠狠爱综合网| 国产v大片淫在线免费观看| 18+在线观看网站| 中文字幕av成人在线电影| 长腿黑丝高跟| 亚洲av免费高清在线观看| 老师上课跳d突然被开到最大视频| 亚洲最大成人中文| 99国产极品粉嫩在线观看| 丰满人妻一区二区三区视频av| 免费搜索国产男女视频| 中文字幕免费在线视频6| 少妇高潮的动态图| 热99在线观看视频| 在线观看午夜福利视频| 国产成人一区二区在线| 高清日韩中文字幕在线| 欧美丝袜亚洲另类| 久久精品91蜜桃| a级毛片a级免费在线| 亚洲一区高清亚洲精品| 日本黄大片高清| 免费看美女性在线毛片视频| 99热这里只有是精品50| 久久国产乱子免费精品| 可以在线观看的亚洲视频| 搞女人的毛片| 亚洲18禁久久av| 日本黄色片子视频| 麻豆久久精品国产亚洲av| 免费大片18禁| 国产又黄又爽又无遮挡在线| 亚洲自拍偷在线| 精品久久久久久久末码| 在线播放无遮挡| 久久久久久久久大av| 午夜激情欧美在线| 日本黄色视频三级网站网址| 欧美激情在线99| 亚洲欧美日韩高清在线视频| 26uuu在线亚洲综合色| 亚洲国产精品成人久久小说 | 两个人视频免费观看高清| 又黄又爽又刺激的免费视频.| 久久久午夜欧美精品| 亚洲高清免费不卡视频| av在线亚洲专区| 丰满人妻一区二区三区视频av| 久久精品国产亚洲网站| 免费观看在线日韩| 免费人成视频x8x8入口观看| 日韩欧美在线乱码| 精品午夜福利在线看| 嘟嘟电影网在线观看| 国产极品精品免费视频能看的| 淫秽高清视频在线观看| 日本三级黄在线观看| 亚洲精品乱码久久久久久按摩| 亚洲av熟女| 国产精品电影一区二区三区| 美女国产视频在线观看| 青春草国产在线视频 | a级毛片a级免费在线| 免费黄网站久久成人精品| 在线观看av片永久免费下载| 国产精品久久久久久av不卡| 国产免费男女视频| 久久人人爽人人爽人人片va| 亚洲美女搞黄在线观看| 自拍偷自拍亚洲精品老妇| 一本久久中文字幕| 免费无遮挡裸体视频| 欧美一区二区国产精品久久精品| 午夜久久久久精精品| 神马国产精品三级电影在线观看| 99久国产av精品国产电影| 国产成人freesex在线| 九色成人免费人妻av| 99热这里只有精品一区| 日韩欧美精品v在线| 老司机影院成人| 两性午夜刺激爽爽歪歪视频在线观看| 长腿黑丝高跟| 国产 一区 欧美 日韩| 成人三级黄色视频| 99热全是精品| 亚洲中文字幕一区二区三区有码在线看| а√天堂www在线а√下载| 啦啦啦韩国在线观看视频| 一区福利在线观看| 久久草成人影院| 12—13女人毛片做爰片一| 嫩草影院新地址| 久久这里有精品视频免费| 国产蜜桃级精品一区二区三区| 久久精品国产亚洲网站| 寂寞人妻少妇视频99o| 丝袜美腿在线中文| 两性午夜刺激爽爽歪歪视频在线观看| 乱人视频在线观看| 国产在线男女| 国产黄a三级三级三级人| 在线播放国产精品三级| 男女下面进入的视频免费午夜| 少妇人妻精品综合一区二区 | 欧美zozozo另类| 亚洲人成网站在线观看播放| 长腿黑丝高跟| 乱码一卡2卡4卡精品| 亚洲精品日韩av片在线观看| a级毛色黄片| 悠悠久久av| 国产精品久久视频播放| 看免费成人av毛片| 成人漫画全彩无遮挡| 国产色婷婷99| 国产一区亚洲一区在线观看| 国产大屁股一区二区在线视频| 97人妻精品一区二区三区麻豆| 国产精品一区www在线观看| 国产精品一区二区在线观看99 | 国产一区二区三区av在线 | 免费观看a级毛片全部| 能在线免费观看的黄片| 你懂的网址亚洲精品在线观看 | 精品99又大又爽又粗少妇毛片| 此物有八面人人有两片| 亚洲最大成人手机在线| 人人妻人人澡人人爽人人夜夜 | 亚洲精品日韩av片在线观看| 久久久久性生活片| 永久网站在线| 久久国产乱子免费精品| 免费看av在线观看网站| 国产三级在线视频| 久久精品国产亚洲网站| 波多野结衣高清无吗| 日韩亚洲欧美综合| 小说图片视频综合网站| 免费人成视频x8x8入口观看| 精品少妇黑人巨大在线播放 | 能在线免费观看的黄片| 精品一区二区三区人妻视频| 性色avwww在线观看| 欧美激情久久久久久爽电影| 69人妻影院| 啦啦啦韩国在线观看视频| 久久中文看片网| 免费黄网站久久成人精品| 国产午夜精品久久久久久一区二区三区| 午夜爱爱视频在线播放| 成人毛片60女人毛片免费| 99riav亚洲国产免费| 白带黄色成豆腐渣| av在线播放精品| 尾随美女入室| 久久久久久久午夜电影| 免费观看精品视频网站| 少妇的逼好多水| 老女人水多毛片| 婷婷六月久久综合丁香| 亚洲久久久久久中文字幕| 中文欧美无线码| 日韩一区二区三区影片| 亚洲av中文av极速乱| 国产精品久久久久久精品电影小说 | 欧美+日韩+精品| 久久久精品94久久精品| 免费人成在线观看视频色| 免费不卡的大黄色大毛片视频在线观看 | 天堂√8在线中文| 99久久成人亚洲精品观看| 男人舔女人下体高潮全视频| 国产精品蜜桃在线观看 | 99久国产av精品国产电影| 女同久久另类99精品国产91| 在线观看午夜福利视频| 国产熟女欧美一区二区| 午夜福利视频1000在线观看| 国产极品精品免费视频能看的| 能在线免费看毛片的网站| 亚洲经典国产精华液单| 中国美女看黄片| 亚洲经典国产精华液单| 一边摸一边抽搐一进一小说| 插逼视频在线观看| 久久午夜福利片| 人人妻人人澡人人爽人人夜夜 | 91av网一区二区| 一级黄片播放器| 日韩一本色道免费dvd| 99在线视频只有这里精品首页| 天堂中文最新版在线下载 | 亚洲,欧美,日韩| 亚洲精品国产成人久久av| 99久久精品一区二区三区| 亚洲精品色激情综合| 国产综合懂色| 久久久久久久久久黄片| 国产高清三级在线| 欧美精品国产亚洲| 亚洲欧美日韩高清在线视频| 又粗又硬又长又爽又黄的视频 | 久久亚洲精品不卡| 亚洲美女搞黄在线观看| 免费av毛片视频| 国产乱人偷精品视频| 国产伦精品一区二区三区视频9| 成年av动漫网址| 久久精品久久久久久噜噜老黄 | 亚洲色图av天堂| 丝袜美腿在线中文| 大香蕉久久网| 一边摸一边抽搐一进一小说| av.在线天堂| 美女cb高潮喷水在线观看| 亚洲中文字幕日韩| 男人和女人高潮做爰伦理| 在线天堂最新版资源| 一本久久中文字幕| 不卡一级毛片| 精品人妻熟女av久视频| 男人舔奶头视频| 免费在线观看成人毛片| 黄片无遮挡物在线观看| 免费看日本二区| 免费观看a级毛片全部| 国产精品伦人一区二区| 日韩精品有码人妻一区| 亚洲图色成人| 爱豆传媒免费全集在线观看| 联通29元200g的流量卡| 日韩强制内射视频| 日本熟妇午夜| 99国产精品一区二区蜜桃av| 国产高清不卡午夜福利| 国产亚洲av嫩草精品影院| 亚洲欧美精品自产自拍| 最近2019中文字幕mv第一页| 国产亚洲5aaaaa淫片| 麻豆av噜噜一区二区三区| 国产精品福利在线免费观看| 中文字幕制服av| 成人国产麻豆网| 国产乱人偷精品视频| 99久久中文字幕三级久久日本| 国产色爽女视频免费观看| 国产成人精品婷婷| 欧美高清成人免费视频www| 成人漫画全彩无遮挡| 一个人看视频在线观看www免费| 国产黄片视频在线免费观看| 国产精品1区2区在线观看.| 国产成人影院久久av| 国产极品精品免费视频能看的| 久久久久网色| 波多野结衣高清无吗| 久久精品久久久久久久性| 91av网一区二区| 国产v大片淫在线免费观看| 一区福利在线观看| 男女那种视频在线观看| 色综合站精品国产| 在线国产一区二区在线| 91在线精品国自产拍蜜月| 一个人看的www免费观看视频| 日韩欧美精品免费久久| 欧美精品一区二区大全| 日本黄色片子视频| 精品国产三级普通话版| 成人美女网站在线观看视频| 久久久久久久午夜电影| 亚洲,欧美,日韩| 久久韩国三级中文字幕| 成年女人看的毛片在线观看| 非洲黑人性xxxx精品又粗又长| 亚洲自拍偷在线| 午夜福利成人在线免费观看| 在线免费观看的www视频| 青春草视频在线免费观看| 成人特级av手机在线观看| 麻豆成人av视频| 亚洲aⅴ乱码一区二区在线播放| 看十八女毛片水多多多| 亚洲av免费高清在线观看| 22中文网久久字幕| 国产一级毛片在线| 日韩制服骚丝袜av| 欧美最黄视频在线播放免费| 国产精品精品国产色婷婷| 日韩,欧美,国产一区二区三区 | av黄色大香蕉| 日韩三级伦理在线观看| 看黄色毛片网站| 国产黄色小视频在线观看| 网址你懂的国产日韩在线| 免费观看的影片在线观看| 精品人妻偷拍中文字幕| 91精品国产九色| 色综合亚洲欧美另类图片| 国产色婷婷99| 偷拍熟女少妇极品色| 亚洲色图av天堂| 日本欧美国产在线视频| 国产av在哪里看| 成人亚洲精品av一区二区| 美女黄网站色视频| 99久久精品一区二区三区| av在线天堂中文字幕| 成年版毛片免费区| 在现免费观看毛片| 91aial.com中文字幕在线观看| 一区福利在线观看| 国产又黄又爽又无遮挡在线| 一边亲一边摸免费视频| 欧美激情国产日韩精品一区| 高清毛片免费观看视频网站| 此物有八面人人有两片| 亚洲人成网站在线播| av又黄又爽大尺度在线免费看 | 成人永久免费在线观看视频| 美女内射精品一级片tv| 久久久久久九九精品二区国产| 夜夜夜夜夜久久久久| 热99在线观看视频| 欧美潮喷喷水| 一夜夜www| 欧美区成人在线视频| 国产精品美女特级片免费视频播放器| av国产免费在线观看| 尤物成人国产欧美一区二区三区| 国产一区二区在线av高清观看| 成人永久免费在线观看视频| 一本久久精品| 亚洲精品久久久久久婷婷小说 | 久久久精品大字幕| 国产精品女同一区二区软件| 在线观看免费视频日本深夜| 少妇人妻精品综合一区二区 | 日本撒尿小便嘘嘘汇集6| 久久精品久久久久久噜噜老黄 | 午夜福利在线观看免费完整高清在 | 黄色一级大片看看| 日本一二三区视频观看| 只有这里有精品99| 亚洲美女搞黄在线观看| 国产精品三级大全| 伦理电影大哥的女人| 欧美色视频一区免费| 欧美又色又爽又黄视频| 校园春色视频在线观看| 国产av不卡久久| 国产成人一区二区在线| 一边摸一边抽搐一进一小说| ponron亚洲| 成人亚洲精品av一区二区| 国产精品一区二区三区四区久久| 搞女人的毛片| 久久九九热精品免费| 日本与韩国留学比较| 亚洲天堂国产精品一区在线| 激情 狠狠 欧美| 一级黄色大片毛片| 精品无人区乱码1区二区| 26uuu在线亚洲综合色| 免费人成在线观看视频色| 国产黄片视频在线免费观看| 精品一区二区三区人妻视频| 中出人妻视频一区二区| 国产高清视频在线观看网站| 免费看光身美女| 午夜精品在线福利| 亚洲精品成人久久久久久| 久久久精品大字幕| 国产高清有码在线观看视频| 两个人的视频大全免费| 欧美成人免费av一区二区三区| 国产亚洲91精品色在线| 成人高潮视频无遮挡免费网站| 1024手机看黄色片| 黄片wwwwww| 大又大粗又爽又黄少妇毛片口| 国产高清有码在线观看视频| av在线蜜桃| 亚洲av不卡在线观看| 国产av不卡久久| 看免费成人av毛片| 亚洲欧美中文字幕日韩二区| 3wmmmm亚洲av在线观看| 啦啦啦韩国在线观看视频| av视频在线观看入口| 欧美精品一区二区大全| 免费黄网站久久成人精品| 麻豆国产97在线/欧美| 免费无遮挡裸体视频| 一进一出抽搐动态| 国产成人91sexporn| 在线播放无遮挡| 午夜免费激情av| 精品人妻视频免费看| 久久久精品大字幕| 岛国在线免费视频观看| 国产精品综合久久久久久久免费| 国产91av在线免费观看| 亚洲精品国产成人久久av| 亚洲成人av在线免费| 一级黄片播放器| 99久久中文字幕三级久久日本| 久久亚洲国产成人精品v| 美女cb高潮喷水在线观看| 精品人妻视频免费看| 日韩大尺度精品在线看网址| 日韩av在线大香蕉| 欧美又色又爽又黄视频| 国产 一区 欧美 日韩| 搡老妇女老女人老熟妇| 午夜福利高清视频| 又爽又黄a免费视频| 免费看美女性在线毛片视频| 1000部很黄的大片| 日本三级黄在线观看| 成人漫画全彩无遮挡| 日本黄大片高清| 亚洲av电影不卡..在线观看| 淫秽高清视频在线观看| 夜夜看夜夜爽夜夜摸| 晚上一个人看的免费电影| 久久久久久久午夜电影| 在线天堂最新版资源| 欧美成人精品欧美一级黄| 97在线视频观看| 熟女电影av网| 亚洲欧美精品综合久久99| 色综合站精品国产| 全区人妻精品视频| 成人亚洲精品av一区二区| 久久久精品94久久精品| 高清午夜精品一区二区三区 | www.色视频.com| 日韩在线高清观看一区二区三区| 久久国内精品自在自线图片| 26uuu在线亚洲综合色| 欧美一级a爱片免费观看看| 国产一区二区三区在线臀色熟女| 精品少妇黑人巨大在线播放 | 成熟少妇高潮喷水视频| av又黄又爽大尺度在线免费看 | .国产精品久久| 久久99热6这里只有精品| 哪里可以看免费的av片| av天堂中文字幕网| 成人二区视频| 亚洲国产欧美人成| 欧美日韩一区二区视频在线观看视频在线 | 黄色欧美视频在线观看| 日韩av在线大香蕉| 亚洲精品日韩在线中文字幕 | 成人漫画全彩无遮挡| 国产女主播在线喷水免费视频网站 |